<DOC>
	<DOCNO>NCT00482703</DOCNO>
	<brief_summary>The objective evaluate cytogenetic response Dasatinib ( BMS-354825 ) administer 24 week subject Imatinib resistant intolerant chronic phase chronic myeloid leukemia ( CML ) daily ( QD ) twice daily . ( BID )</brief_summary>
	<brief_title>A Study Dasatinib Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Philadelphia chromosome positive bcrabl gene positive Chronic phase Chronic Myelogenous Leukemia ( CML ) subject must primary acquire resistance Imatinib mesylate intolerance imatinib mesylate Performance status ( general condition ) specify Eastern Cooperative Oncology Group : 02 Men woman , age 20 75 Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study 3 month study manner risk pregnancy minimize Subjects eligible willing undergo transplantation prestudy Women pregnant breastfeeding Uncontrolled significant cardiovascular disease History significant bleeding disorder unrelated CML Adequate hepatic function Adequate renal function Medication increase bleed risk Medication change heart rhythm Subjects compulsory detain legal reason treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Imatinib resistant intolerant chronic phase CML</keyword>
</DOC>